March 19, 2025 — Intriguing observations on the effect of retatrutide on cancer progression in mice appeared Friday in NPJ Metabolic Health and Disease. Retatrutide is the first triple agonist to progress in clinical development for obesity. Lilly said recently that they expect to release phase three clinical trial data for it later this year – earlier than previously […]
November 26, 2024 — For the second time this year, we have a meta-analysis of RCTs with GLP-1 medicines that affirms cardiorenal benefits in outcome studies. This latest study appears in Lancet Diabetes and Endocrinology. Lead author Sunil Badve described the importance of his analysis: “This is the first study to show a clear benefit of GLP-1 receptor agonists […]
August 13, 2024 — For the second time in the past few months, a signal from the surveillance of GLP-1 agonists is surfacing to suggest that these drugs may offer a risk reduction strategy for cancer. Earlier, the signal came from a study of persons receiving treatment for diabetes. The present study, presented at the recent annual meeting for […]
May 2, 2023 — Yet again we are reminded that bariatric surgery has quite an impressive record for improving the health of people with obesity. In a retrospective cohort study of 55,789 patients receiving bariatric surgery, risk of obesity-related cancer came down by half. Researchers matched the non-surgical control group using propensity scores for demographics, comorbidity, hormone therapy, and […]
